Clinical Recruitment

Big Data can help in a range of steps included in clinical trials such as patient profiling so as to identify the right candidates through analytics of demographic information and historical data, assessing medication availability, surveying past clinical trial events, intervention for appropriate drug dosage, and remote patient monitoring. Moreover, it helps recognize the possible adverse and undesirable effects of a new drug even before they are

1 Understand the recruitment and selection processes in health and social care or children and young people’s settings

In the field of medicine, clinical trials are known to be a reliable source of information. Although ethical issues do arise, to which the theory of equipoise was proposed, which states that there should be a balance of forces of interests (Weijer et al., 95). There are two types of equipoise; clinical and theoretical. Clinical equipoise is the assignment of multiple treatments to be tested on patients with the disagreement in the medical community in which medical professionals have differing views that one treatment is better than the others (Weijer et al., pg. 97). Theoretical equipoise is between a physician and researcher and the belief that the risks and benefits of the treatments are in perfect balance (Wiejer et al., 96). The differing factor of the two, being that clinical equipoise focuses on the difference in views of certain treatments involving much of the medical community to form an insightful conclusion on the procedure to which the evidence supporting each treatment does not have to be balanced, whereas theoretical equipoise focuses on the equal amount of risks and benefits within each treatment (Weijer et al., 97). With that being said I personally believe researchers must be in a state of clinical equipoise to run morally acceptable clinical trials.

Bringing Henrietta to Life: Creating Dialogue on Disparities across Disciplines Henrietta Lacks was a woman who made an eye-opening breakthrough in medicine in the early 1950s. Her cells were the first immortal cells to be discovered which paved the way for developing the polio vaccine, cloning, gene mapping, in-vitro fertilization, and more. Unfortunately, there are two sides to every story. Although, modern medicine would not be where it is today without Hela cells, Henrietta’s family continued to struggle with her legacy because of the health disparities associated with ethics, race, and medicine. Henrietta’s cells were taken without her knowledge and used to cure various medical conditions.

Our country is one where every day, new medical treatments and medicines are being discovered and being approved to help Americans battle all of the different diseases and conditions that affect us. In order for us to be able to get access to those medications and treatments, many people agree to become part of clinical trials, they are the first to receive the treatments, this helps to understand how the body will be affected and if the medication will be effective. People who are part of these clinical trials, go through extensive medical testing, and they must be of sound mind and

They deceived them for 40 years by making them think they were receiving treatments for “bad blood” when in fact they were withholding treatment. However, in present day, researchers must comply with guidelines and undergo a review panel to be approved. Participants must be informed of the study and its risks as well as the right to decline participation at any given time. The subjects must also be competent and be able to understand what is happening in the experiment as well as its

The author believes that biomedical research is the way of better understanding medicine and without randomized clinical trials the field of medicine will have insufficient information. He argues that randomized clinical trials are the most scientifically sound and ethically correct means of evaluating new therapies. The belief of a physician being unethical when running randomized clinical trials is rejected by this article because previous trials on patients can have a better outcome on future patients. This article stresses that randomized clinical trials must be carefully designed that has an intended purpose of gathering data to improve the wellbeing of patients. If the patient is to endure a clinical trial he/she must be properly informed of the risks of the trial and the health of the patient should be high priority. Overall this article explains the importance of randomized clinical trials and debunks the idea of randomized clinical trials as being unethical. This article uses a utilitarian point of view and gives reasons why these trials can be in the best interests for both the patient and society.

There are many ethical issues in the healthcare field. These issues range from insurance coverage, senior care, childhood immunizations, beneficence, abortion, medicinal marijuana, honesty and medical research (Fritzsche, D., 2004). Today we will discuss the ethical concerns in only one aspect of heath care and that topic is research (Benatar, S., 2000). Medical research is necessary in order to make strides in health care, introduce new medications, to discover new symptoms and disorders and to test new treatment options for current medical problems. Students of medicine, universities and pharmaceutical companies conduct this research primarily. Much of this research is time consuming and costly, therefore obtaining funding is not

Healthcare jobs aren’t always easy to find on your own. The job hunt itself is stressful, time-consuming, and challenging. A recruitment agency that focuses on the healthcare industry is a big help for nurses, doctors, midwives, and other healthcare jobs.

Clinical trials are the gold standard of experimental design to examine the effect of a clinical intervention on patients or populations. Recruiting targeted number of subjects in a timely manner is essential to the success of a clinical trial. Failure to enroll and retain expected number of participants could result in underpowered study (Page & Persch, 2013). One of the challenge for clinical trial recruitment is the clinical trial eligibility criteria are mostly written in free text, which cannot be easily interpreted by computer for automatic patient for the clinical trial.

Patient recruitment is one of the biggest obstacles, and challenges, in clinical research, and a major cause of delays in developing promising new treatments. Nearly 30% of the time spent in clinical trials is dedicated to patient recruitment and enrollment, making it the most time intensive of all tasks.

Another question we come across in this case is "Should these pharmaceutical companies have a moral obligation to make the drugs available to the people who they performed clinical trials on?". Again we clearly should see that the pharmaceutical companies should allow the access of these drugs to the people that are being used to test their products. There is a huge risk for these people who are taking a new drug, not knowing exactly what the outcome can be and are merely treated as guinea pigs for the

Before the recruiting process begins, it’s important for the investigator to “buy in” to the clinical rationale and approach: he or she must feel confident that the proposed intervention has meaningful potential in the treatment of the target disease. This belief can be based on preliminary studies, biological plausibility, and presence of a true unmet need. Without the investigator’s commitment in the intervention at hand, it will be virtually impossible to recruit potential patients and come to an agreement with the patient that enrolling in a study is the most appropriate plan-of-action. If the investigator is enthusiastic about the potential of the therapy, the next step is deciding which patients are the most suitable candidates.

Innovation and the “Change” process have gripped the clinical research Industry in the last few years. Evolution in technology and Risk Management processes consequently lead to release of the latest International Council of harmonization (ICH) Good Clinical practice (GCP) E6 R2 step 4 on Nov 30 2016. Other highlights of the Research Industry are revision to the “Common Rule” “to reduce burden, delay and ambiguity for investigators”, the Food and Drug administration (FDA) encouraging Diversity because there is variability of drug response and FDA’s initiatives for paperless trials with the release of multiple guidance documents addressing technology tools including electronic informed consent (FDA, 2017; HHS, 2017 and

Innovation and the “Change” process have gripped the clinical research Industry in the last few years. Evolution in technology and Risk Management processes consequently lead to release of the latest International Council of Harmonization (ICH) Good Clinical Practice (GCP) E6 R2 step 4 in Nov 2016. Change in the Clinical Research landscape also lead to revisions towards modernization and reinforcement of the “Common Rule” in Jan 2017 besides the Food and Drug administration’s (FDA) ongoing initiatives for paperless trials with the release of multiple guidance documents including electronic informed consent (Federal Register, 2017 and Mitchel & Helfgott, 2017). Other highlights of the Research Industry are FDA propagating